Loading asset research
Fate Therapeutics Inc. Common Stock
FATENasdaq · USD · StocksQuote as of · Exchange session not verified$2.36
-3.09%
Today
FATE
Loading 1D prices…
Market cap
$279.2M
Volume
1.2M
52w high
$3.2352w low
$0.95Company profile
Fate Therapeutics Inc. Common Stock
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
San Diego, CA, United States
Employees
161
Fiscal year end
1231
CIK
1434316
Session & valuation
Open$2.43
Previous close$2.43
Day high$2.43
Day low$2.27
30-day avg. volume1.5M
Outstanding shares119.8M
Diluted EPS-$1.15
Latest annual period
P/E (trailing)-2.05
P/E (forward)-2.41
Price / book1.77
Beta2.55
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| LXEOLexeo Therapeutics Inc. Common Stock | $278.3M | $0.00 | — | -$1.86 | -6.11% | Buy |
| PALIPalisade Bio Inc. Common Stock | $273.6M | $0.00 | — | -$0.30 | -7.81% | Buy |
| IVVDInvivyd Inc. Common Stock | $273M | $53.4M | -98.25% | -$0.30 | +1.44% | Buy |
| IKTInhibikase Therapeutics Inc. Common Stock | $293M | $0.00 | — | -$0.49 | -3.49% | Buy |
| XFORX4 Pharmaceuticals Inc. Common Stock | $297.4M | $35.1M | -225.55% | -$1.87 | -3.22% | Buy |